Lupin Receives USFDA's Form 483 with Three Key Observations
Synopsis
In a significant regulatory development, Lupin has received a Form 483 from the USFDA highlighting three observations at its New Jersey facility. The company is determined to address these findings promptly while ensuring compliance with cGMP standards. This follows a similar incident at its Ankleshwar facility in India last month.
Key Takeaways
Lupin received a Form 483 with three observations from the USFDA.
The inspection occurred at their Somerset, New Jersey facility.
Lupin will address the observations in a timely manner.
The company emphasizes its commitment to cGMP compliance.
This follows a similar incident at their Ankleshwar facility in March.
New Delhi, April 18 (NationPress) On Saturday, prominent pharmaceutical company Lupin announced that the US health authority has issued a 'Form 483' with three remarks concerning its manufacturing facility located in Somerset, New Jersey, after a recent inspection.
In a regulatory disclosure, the firm stated that the inspection by the US Food and Drug Administration (USFDA) took place this week, spanning from April 13 to April 17.
"The inspection concluded with the issuance of a Form 483, encompassing three observations," the company reported.
Lupin further emphasized its commitment to addressing the observations and responding to the USFDA within the required timeframe.
The company reiterated its dedication to adhering to current Good Manufacturing Practices (cGMP) across all its facilities.
Previously, in March, the USFDA completed an inspection at Lupin’s Ankleshwar manufacturing facility in India—conducted from March 2 to March 7—which also resulted in a Form 483 with two observations.
At that time, Lupin indicated it would address the findings and respond within the mandated timeline while continuing to comply with cGMP standards.
The USFDA issues a Form 483 to a company’s management at the end of an inspection when conditions observed may indicate violations of the Food, Drug, and Cosmetic (FD&C) Act and associated regulations.
On Friday, Lupin's shares closed at Rs 2,322.50, marking a decline of 0.19 percent on the NSE. Additionally, the pharmaceutical stock reached a 52-week peak of Rs 2,377.60 and a low of Rs 1,836.80 on the exchange.
Point of View
It's essential to monitor regulatory actions such as the USFDA's issuance of a Form 483. These observations reflect critical compliance issues that must be addressed to ensure public safety and maintain industry standards. Lupin's commitment to resolving these matters is crucial for its reputation and operational integrity.
NationPress
1 May 2026
Frequently Asked Questions
How many observations were noted in Lupin's Form 483?
The USFDA issued a Form 483 to Lupin with three observations.
What is Lupin's response to the Form 483?
Lupin has stated that it will address the observations and respond to the USFDA within the designated timeframe.
Where is Lupin's facility that was inspected?
The inspected facility is located in Somerset, New Jersey.
When did the USFDA conduct the inspection at Lupin's facility?
The inspection took place from April 13 to April 17.
